These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21283024)

  • 1. Nebivolol: an endothelium-friendly selective β1-adrenoceptor blocker.
    Gao Y; Vanhoutte PM
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):16-21. PubMed ID: 21283024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebivolol: impact on cardiac and endothelial function and clinical utility.
    Toblli JE; DiGennaro F; Giani JF; Dominici FP
    Vasc Health Risk Manag; 2012; 8():151-60. PubMed ID: 22454559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
    Ignarro LJ
    Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
    Gupta S; Wright HM
    Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol.
    Fang Y; Nicol L; Harouki N; Monteil C; Wecker D; Debunne M; Bauer F; Lallemand F; Richard V; Thuillez C; Mulder P
    J Mol Cell Cardiol; 2011 Aug; 51(2):168-76. PubMed ID: 21640121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nebivolol: endothelium-mediated vasodilating effect.
    Ritter JM
    J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S13-6. PubMed ID: 11811387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE; Philipp T
    Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
    Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
    Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
    Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
    J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring vascular benefits of endothelium-derived nitric oxide.
    Cockcroft JR
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):177S-183S. PubMed ID: 16373196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation.
    Weiss R
    Vasc Health Risk Manag; 2006; 2(3):303-8. PubMed ID: 17326335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebivolol: the somewhat-different beta-adrenergic receptor blocker.
    Münzel T; Gori T
    J Am Coll Cardiol; 2009 Oct; 54(16):1491-9. PubMed ID: 19815121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
    Perros F; Ranchoux B; Izikki M; Bentebbal S; Happé C; Antigny F; Jourdon P; Dorfmüller P; Lecerf F; Fadel E; Simonneau G; Humbert M; Bogaard HJ; Eddahibi S
    J Am Coll Cardiol; 2015 Feb; 65(7):668-80. PubMed ID: 25677428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol.
    Kuroedov A; Cosentino F; Lüscher TF
    Cardiovasc Drug Rev; 2004; 22(3):155-68. PubMed ID: 15492765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
    Ignarro LJ
    Blood Press Suppl; 2004 Oct; 1():2-16. PubMed ID: 15587107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tempol-nebivolol therapy potentiates hypotensive effect increasing NO bioavailability and signaling pathway.
    Bertera FM; Santa-Cruz DM; Balestrasse KB; Gorzalczany SB; Höcht C; Taira CA; Polizio AH
    Free Radic Res; 2014 Feb; 48(2):109-18. PubMed ID: 24074298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasodilator effects of nebivolol in a rat model of hypertension and a rabbit model of congestive heart failure.
    de Groot AA; Mathy MJ; van Zwieten PA; Peters SL
    J Cardiovasc Pharmacol; 2007 Jul; 50(1):56-60. PubMed ID: 17666916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.
    Chlopicki S; Kozlovski VI; Gryglewski RJ
    J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):615-24. PubMed ID: 12512696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.
    Mason RP; Kubant R; Jacob RF; Walter MF; Boychuk B; Malinski T
    J Cardiovasc Pharmacol; 2006 Jul; 48(1):862-9. PubMed ID: 16891916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.